A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
about
Targeting mTOR for the treatment of AML. New agents and new directionsTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesThe physiology and pathophysiology of rapamycin resistance: implications for cancerThe mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogsPhase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.SYK regulates mTOR signaling in AML.Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingThe phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.NF1 inactivation in adult acute myelogenous leukemiaElacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaInhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat modelHigh dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Efficacy and comparative effectiveness of sirolimus as an anticancer drug.Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaThe hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.Salvage therapy for relapsed or refractory acute myeloid leukemiaPhase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsTargeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesAcute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.Mammalian target of rapamycin as a target in hematological malignancies.Utility of mTOR inhibition in hematologic malignancies.Novel and emerging drugs for acute myeloid leukemiaMechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C.Targeting the mTOR Pathway in Leukemia.m-TOR inhibitors and their potential role in haematological malignancies.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy.Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients.
P2860
Q24617223-0FD916E2-3991-4D1E-9DDB-E032B7073A4EQ26829652-5976F56F-D0F6-4B43-BD2C-9B2109E7CF07Q28478235-A2554B81-18F3-4ADA-BCA4-C1467299E640Q33437313-6017DC50-DC27-471C-BF08-164B1775691FQ33603032-3D8DB33A-E8C9-4A25-927E-B10BC8478B37Q33618884-5F1B4A8C-709F-4071-AB5E-042C20067C1CQ33641643-79F0D90D-0FEA-4E1A-B09F-A787F49DC066Q33752594-C38EB3E5-AEA3-4DF8-B24C-19C952F12148Q34024558-46A7524B-D87A-4835-9861-66C54B5942E8Q34065032-2505E836-151E-49FB-A6F6-F566ECA69CCBQ34314177-602DA156-30F7-4B99-A8F8-1CD43D393748Q34325616-ACA9F1C3-BAFD-49FE-9594-65D8CA8D1235Q34500856-B2C9B077-40FE-4C5E-B072-C55A3999F2E9Q34715598-A1F9E7C8-2E73-428D-A105-3718524D0394Q34891527-3E92CF72-682B-49D5-B9D9-4C4DC897B150Q35091507-EF0D2A20-D4CF-4FA1-9387-A78E6D788BE5Q35836566-A0C2082E-4E35-4E80-AC56-AED683D3951CQ35843230-AE0710EE-3ED9-4DB9-A23D-A76B42D3002BQ36214081-F457C34E-194E-4847-A2EB-00224F67C481Q36352535-0112DC60-AF48-4590-BBF4-884FA03A3E1DQ36545229-729D9579-56B0-49C2-B98D-43A16B04603AQ36612564-F3C7D937-28DD-4F04-9E7E-4C876E11A54AQ37046021-B01DBDC1-3206-47A6-B635-3A086DCBADF0Q37132224-9A741EF2-E780-4462-A29C-699AEB4C383FQ37132788-73D944A7-6A91-4AB8-A73B-F04D743F4807Q37364509-4D2A41CB-DD2E-4512-A13A-7D509758D23DQ37779489-5C5C58C0-51DD-43E4-863A-667FFB0E2D10Q37866136-D6A1804A-DF8B-4942-BB2B-81528DF62316Q37883723-2D94B054-7B2F-48EB-B901-C6A9BFBAAC09Q38000711-7E1D833C-4C2F-4E50-B257-5CB17D945158Q38104492-26233657-BC12-4B10-8C52-AC84051412C3Q38218128-2ACC5599-70F5-4ECF-9960-2B5B9A3130E2Q38521775-4814C5CE-136D-4F19-88D6-B9DBF6B117E1Q38655657-AE9F9062-92B3-488E-AF38-99D450786368Q38790630-44B0C551-B277-4840-BF33-3B3B2A6B35F6Q39113506-DC320628-B5B4-463B-9D61-E770AFCE2FBAQ39326047-AF4A8D74-E10A-4DA7-AE98-6A332F83E074Q41817864-90ED462C-74A0-40D0-9DD3-ABECE2B40433Q41891342-8F5FC71C-2789-49FE-8B8C-5B8246D18B66Q42541266-8C5B7E06-C216-4048-BFC0-FA004C38F3CB
P2860
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@en
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@nl
type
label
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@en
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@nl
prefLabel
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@en
A phase I study of the mammali ...... ry acute myelogenous leukemia.
@nl
P2093
P1476
A phase I study of the mammali ...... ory acute myelogenous leukemia
@en
P2093
Alan M Gewirtz
Alexander E Perl
Alison W Loren
Cezary R Swider
David L Porter
Donald E Tsai
Edward A Stadtmauer
Elizabeth O Hexner
Jamil K Dierov
P304
P356
10.1158/1078-0432.CCR-09-0842
P407
P50
P577
2009-10-20T00:00:00Z